Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Soluble plasma HLA peptidome as a potential source for cancer biomarkers

Michal Bassani-Sternberg, Eilon Barnea, Ilan Beer, Irit Avivi, Tami Katz, Arie Admon and Peter Cresswell
Proceedings of the National Academy of Sciences of the United States of America
Vol. 107, No. 44 (November 2, 2010), pp. 18769-18776
Stable URL: http://www.jstor.org/stable/25748571
Page Count: 8
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Soluble plasma HLA peptidome as a potential source for cancer biomarkers
Preview not available

Abstract

The HLA molecules are membrane-bound transporters that carry peptides from the cytoplasm to the cell surface for surveillance by circulating T lymphocytes. Although low levels of soluble HLA molecules (sHLA) are normally released into the blood, many types of tumor cells release larger amounts of these sHLA molecules, presumably to counter immune surveillance by T cells. Here we demonstrate that these sHLA molecules are still bound with their authentic peptide repertoires, similar to those of the membranal HLA molecules (mHLA). Therefore, a single immunoaffinity purification of the plasma sHLA molecules, starting with a few milliliters of patients’ blood, allows for identification of very large sHLA peptidomes by mass spectrometry, forming a foundation for development of a simple and universal blood-based cancer diagnosis. The new methodology was validated using plasma and tumor cells of multiple-myeloma and leukemia patients, plasma of healthy controls, and with cultured cancer cells. The analyses identified thousands of sHLA peptides, including some cancer-related peptides, present among the sHLA peptidomes of the cancer patients. Furthermore, because the HLA peptides are the degradation products of the cellular proteins, this sHLA peptidomics approach opens the way for investigation of the patterns of protein synthesis and degradation within the tumor cells.

Page Thumbnails

  • Thumbnail: Page 
[18769]
    [18769]
  • Thumbnail: Page 
18770
    18770
  • Thumbnail: Page 
18771
    18771
  • Thumbnail: Page 
18772
    18772
  • Thumbnail: Page 
18773
    18773
  • Thumbnail: Page 
18774
    18774
  • Thumbnail: Page 
18775
    18775
  • Thumbnail: Page 
18776
    18776